AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker…
Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy…
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership…
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing…
Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newbornsSAN…
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for…
BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage…
Safety Shot is Not GBB Drink Lab, Inc. (GBB) and never acquired GBB as falsely claimed by FSD Pharma; Only…
BASKING RIDGE, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells…